Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050023/S207

Renamic Neo

Biotronik, Inc. · Decision date Apr 24, 2026

FDA DECISIONP050023/S207

What did the FDA approve?

FDA records P050023/S207 as a supplement to PMA P050023, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 24, 2026.

FDA approval order statement

approval for display and programming head updates to Renamic Neo programmer
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Apr 24, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P050023/S207
Regulatory pathway
PMA supplement
Product code
MRM
Decision code
APPR
Decision date
Apr 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.

Product code
MRM
FDA device class
3

For the original device and its historical approval scope, see PMA P050023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P050023 · Original PMA

    TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD

  2. P050023/S197 · Related supplement

    CardioMessenger Smart 4G

  3. P050023/S200 · Related supplement

    Acticor 7 VR-T (429526); Rivacor 7 VR-T (429536); Rivacor 5 VR-T (429565); Rivacor 3 VR-T (429574); Acticor 7 VR-T DX (4

  4. P050023/S201 · Related supplement

    Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Ilivia 7 DF4 VR-T 40462

  5. P050023/S202 · Related supplement

    Ilivia 7 VR-T DX; Intica 7 VR-T DX; Intica 5 VR-T DX; Ilivia 7 VR-T; Ilivia 7 DF4 VR-T; Intica 7 VR-T; Intica 7 DF4 VR-T

  6. P050023/S203 · Related supplement

    Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Intica 7 VR-T 404634; I

  7. P050023/S196 · Related supplement

    Acticor 7 VR-T; Rivacor 7 VR-T; Rivacor 5 VR-T; Rivacor 3 VR-T; Acticor 7 VR-T DX; Rivacor 7 VR-T DX; Rivacor 5 VR-T DX;

  8. P050023/S199 · Related supplement

    Acticor Sky HF-T 481986, Rivacor Sky HF-T 481991, Rivacor Rise HF-T 482017, Rivacor Aura HF-T 482013, Acticor Sky HF-T Q

  9. P050023/S207 received

    Application receipt date recorded by FDA.

  10. P050023/S206 · Related supplement

    TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD

  11. P050023/S205 · Related supplement

    TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD

  12. P050023/S208 · Related supplement

    Acticor 7 VR-T (429526); Rivacor 7 VR-T (429536); Rivacor 5 VR-T (429565); Rivacor 3 VR-T (429574); Acticor 7 VR-T DX (4

  13. P050023/S207 · FDA decision

    Real-Time Process

  14. P050023/S210 · Related supplement

    Acticor 7 VR-T, Rivacor 7 VR-T, Rivacor 5 VR-T, Rivacor 3 VR-T, Acticor 7 VR-T DX, Rivacor 7 VR-T DX, Rivacor 5 VR-T DX,

  15. P050023/S212 · Related supplement

    Acticor 7 VR-T DX (429525); Acticor 7 VR-T DF4 ProMRI (429526); Rivacor 3 VR-T DF4 ProMRI (429574); Rivacor 5 VR-T DF4 P

  16. P050023/S211 · Related supplement

    PSW 2601.U, NEO 2601.U, Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, R

  17. P050023/S204 · Related supplement

    Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Intica 7 VR-T 404634; I

  18. P050023/S214 · Related supplement

    Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, Rivacor Sky HF-T QP, Riva

  19. P050023/S213 · Related supplement

    Acticor Sky HF-T 481986; Rivacor Sky HF-T 481991; Rivacor Rise HF-T 482017; Rivacor Aura HF-T 482013; Acticor Sky HF-T Q

  20. P050023/S215 · Related supplement

    Ilivia 7 VR-T DX DF-1 ProMRI Ilivia 7 VR-T DF-1 ProMRI Ilivia 7 VR-T DF4 ProMRI Intica 7 VR-T DX DF-1 ProMRI Intica 7 VR

  21. P050023/S216 · Related supplement

    Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, Inlexa 7 VRT, Inlexa 7 VRT

Timeline entries are records held by MedtechLedger for P050023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050023

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik, Inc.PMA approvalAug 10, 2006FDA
Biotronik, Inc.PMA supplementAug 22, 2025FDA
Biotronik, Inc.PMA supplementSep 11, 2025FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementOct 1, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementOct 24, 2025FDA
Biotronik, Inc.PMA supplementDec 18, 2025FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementFeb 11, 2026FDA
Biotronik, Inc.PMA supplementMar 5, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.PMA supplementJun 24, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
BIOexpressP050023/S209
Biotronik, Inc.PMA supplementOct 16, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA

Explore the linked device profile

Other records with product code MRM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records